The Department of Health and Social Care (DHSC) has added further 28 new products to the list of 'Drugs for which Discount is Not Deducted' (DND) in Part II
of the Drug Tariff from 1 August 2022.
PSNC said, "It will continue its work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual
item' criteria and make applications to NHSBSA and DHSC, accordingly."
A total of 529 products have been granted DND status following checks made by PSNC within the past 26 months.
Nine more new products have been classed as 'Drugs for which Discount is Not Deducted' (DND) from 1 July 2022, announced Department of Health and Social
Care (DHSC).
This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating
Committee.
The Committee had made an application to DHSC and NHSBSA for the following 9 products to be added to the DND list of Individual items to which the discount
deduction scale will no longer apply from July 2022:
Fludrocortisone 50micrograms/5ml oral suspension (Group)
Lorazepam 1mg/5ml oral suspension (Group)
Lorazepam 500micrograms/5ml oral suspension (Group)
Zopiclone 3.75mg/5ml oral solution (Group)
Zopiclone 7.5mg/5ml oral solution (Group)
GA explore5 oral powder 12.5g sachets
HCU explore5 oral powder 12.5g sachets
MSUD explore5 oral powder 12.5g sachets
TYR explore5 oral powder 12.5g sachets
The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.
The NHS Business Services Authority (NHSBSA) has published the Drug Tariff Category M price list for July which reflects an increase in reimbursement
level of approximately £5m per quarter.
An adjustment of -£23.8m was announced, in light of the results of the margin survey (latest result up until end of December 2022), and the phasing down of the
additional £100m agreed across years 4 and 5 as part of the Community Pharmacy Contractual Framework and uplifts for underlying market prices
(between January - March 2023).
Community Pharmacy England has agreed the adjustments based on the analysis of margin delivery and on current projections for 2023/24.
It said: "The objectives are to ensure full delivery of agreed margin and smooth delivery as much as possible. As always, the impact on individual pharmacies
will vary depending on dispensing mix."
The Department of Health and Social Care has updated the list of community pharmacies eligible for the Pharmacy Access Scheme (PhAS) and approved 43 cases
out of 63 applications, bringing the the total number of eligible pharmacies in England to 1,445.
Earlier this year, NHS England and NHS Improvement (NHSE&I) invited community pharmacy contractors to apply for a review if they believed there were any inaccuracies
in relation to pharmacy premises addresses or unforeseen circumstances affecting access, such as a permanent roadblock.
Submitted applications were reviewed by the relevant NHSE&I regional pharmacy contract team, and determined by the relevant pharmaceutical services regulations
committees (PSRC).
Due to the workload pressures seen over winter, the review deadline was extended, giving contractors applying for a review two full months to complete their
applications. This also pushed back the announcement of the outcome of the review, but where an application has been successful, PhAS payments will be backdated
to the start of the scheme.
The Pharmaceutical Services Negotiating Committee (PSNC) has challenged price concessions imposed by the Department of Health and Social Care (DHSC) on some
of the medicines.
It has raised concerns on the process for setting price concessions to senior government officials responsible for medicines supply, warning that the system is not
working in the current environment from a community pharmacy contractor perspective.
"When a new government takes over next week, this will be one of several urgent topics being raised by PSNC to new ministers, alongside the fuel price crisis,
inflationary pressures and winter pressures on pharmacy businesses," said PSNC.
The final update to August price concessions was announced yesterday taking the total concessions granted to a record 138 for August. PSNC said: "Of those, 99 were
in line with PSNC requests, but prices for 39 lines were imposed by the Department of Health and Social Care (DHSC): those impositions do not match the purchase
prices reported by contractors and the evidence of market prices which we passed on to DHSC. In particular, the final imposed prices of Apriprazole and Temazepam
tablets has generated a lot of concern amongst contractors due to the large variation between their reimbursement prices and purchase prices during the month of
August."